Group items tagged

Patients suffering from chronic and episodic migraine attacks are set to benefit from a groundbreaking recommendation by the National Institute for Health and Care Excellence (NICE) regarding a new medication. The atogepant, a first-of-its-kind preventive drug for migraine, offers hope for those grappling with this debilitating condition and can be taken orally. Published as part of the final guidance draft, NICE has greenlit the atogepant, also known as Aquipta and manufactured by AbbVie, as an option for preventing both chronic and episodic migraines in adults. Specifically, this recommendation is for individuals who have experienced at least four migraine days per month and have failed to find relief with at least three previous preventive treatments. With approximately 4.5 million people in the UK affected by various forms of migraine, this new recommendation marks a significant advancement in migraine management as the condition significantly impacts patients' day-to-day activities as well as places a heavy burden on the NHS and the wider economy.

Superdrug Online Doctors has made travelling easy ahead of Easter by introducing jet lag 'melatonin' tablets into its travel services portfolio to help those taking long haul flights. The company has seen an 287 per cent increase in demand for its travel services and products. Malaria treatment is up by 272 per cent, gut health products up by 317 per cent, jet lag melatonin tablets increasing by 900 per cent since launch and Period Delay services which offer more choice when it comes to the timing of periods up by 195 per cent year-on-year. Dr Sara Kayat, Superdrug's medical ambassador, comments: "Jet lag is a temporary sleep problem that affects people who travel across different time zones. It can occur when your internal clock, the function that lets your body know when to stay awake and when to sleep, is disrupted by a new time zone and puts your internal clock out of sync. Melatonin is a hormone we produce to help regulate our sleep cycles, and a synthetic version can be taken in the short term to manage jet lag."

HayMax, manufacturer of organic, drug-free allergen barrier balms for hay fever, dust, and pet allergies, has recently won the 2023 Global 100 awards. The HayMax balm, applied around nostril rims and eye bones, is an innovative allergen blocker against pollen, dust, and pet allergens entering the body. Independent university research confirms it traps over a third of pollen, along with dust mites and pet dander, before they enter the body, according to HayMax. The drug-free balm is Soil Association-certified organic, comprising 100 per cent natural ingredients. Safe for children, pregnant, and breastfeeding women, it holds the Vegetarian Society Approved trademark. This award has come as a complete surprise to us at HayMax," said HayMax MD, Max Wiseberg. "Being held in such high regard through this global recognition is truly delightful." "The Global 100 aims to offer readers insight into firms that excel in their chosen specialties, and the award underscores hard work and innovation of various companies," said its organisers.

The number of people suffering from addiction is at an all time high, with more people seeking treatment across the USA due to the fentanyl crisis, but new studies have shown that addiction drugs may not only be able to aid those suffering from the deadly disease, but also aid people suffering from long COVID. While there has long been research underway to find a cure for the likes of alcoholism and drug addiction, it turns out naltrexone, a drug used in the addiction treatment space, is helping people who have been suffering from headaches, seizures and fatigue as a result of long COVID. According to Dr. Paul Valbuena at The River Source, an Arizona drug rehab, naltrexone is typically used by rehab centers and prescribed to patients suffering from addiction to reduce cravings and the feeling of euphoria associated with substance use disorder, giving patients clarity and focus to concentrate on recovery. Thanks to a recent report, that has also been revealed to be the case for those suffering with long COVID too, with Lauren Nichols, a long COVID sufferer from Chicago being prescribed the drug by her doctor. She found that the drug helped quell her seizures and headaches, alowing her to think clearly and get on with her life as normal. It's been a similar story for other patients too, and has marked a major breakthrough in the bid to help those who are still suffering in the aftermath of the pandemic.

Nasofed Anti Viral Nasal Spray, from EM Pharma, is delighted to welcome Dr Sarah Jarvis as medical adviser for its winter colds and flu consumer awareness campaign. Sarah is well known as a trusted and reliable source of medical advice through her various media roles as Resident GP on BBC R2's The Jeremey Vine Show, Good Morning Britain, Channel 5 and ITV News. Says Paul Walsh, EM Pharma Managing Director: "Dr Sarah will be offering advice on how people can best protect themselves and their families against seasonal and year-round viruses, including the use of Nasofed anti viral thixotropic nasal spray as an extra layer of protection particularly in situations of increased viral risk." Dr Sarah adds: "Viruses continue to affect our daily lives, whether that be year-round viruses or more seasonal viruses such as colds and flu and RSV, all of which are expected to be particularly prevalent this year. In situations of increased viral risk, a thixotropic nasal spray delivering anti viral ingredients will help protect you. It's a real step forward in virus prevention, not just for colds and flu, but also year-round viruses."

Sun Pharmaceutical Industries, India's largest drugmaker by revenue, reported a better-than-expected 5.2 per cent rise in third-quarter profit on Tuesday, driven by higher sales of its specialty drugs. The company, known for its consumer healthcare products such as Revital vitamins and pain relief medicine Volini, said it earned a consolidated net profit of 21.66 billion rupees ($265.23 million) in three months ended Dec. 31, up from 20.59 billion rupees last year. Analysts, on average, had expected the company to report a profit of 21.26 billion rupees, according to Refinitiv IBES data. Total revenue from operations climbed nearly 14 per cent to 112.41 billion rupees. Input costs rose 8.5 per cent. Drug sales in India rose 7.1 per cent to 33.92 billion rupees, whereas sales in the United States climbed 16.6 per cent to 34.66 billion rupees, with each of the two regions accounting for 31 per cent of the company's total consolidated sales. The company, founded in 1983, makes over-the-counter medications, anti-retrovirals and active pharmaceutical ingredients for chronic and acute treatments.

In recent years, there has been an increased focus on the importance of health. People are looking for ways to improve their health and live a longer, more productive life. There are many different places that people can go to work on their health, but some are better than others. Here is a list of the top six places to work on your health. 1) MEDICAL SPA A medical spa is a place where people can go to improve their health. medical spas offer a variety of services, including skin care, laser hair removal, and body contouring. They also offer a variety of medical treatments, such as laser surgery and Botox injections. Medical spas offer a number of benefits to their patients. First, they offer a wide variety of services that can help people improve their health. Second, they offer a number of medical treatments that can help people address specific health concerns. Third, they offer a relaxing environment where people can come to improve their health and wellbeing. No matter if you're looking for a medical spa in Alexandria, VA, New York, or any other state, they can be a great place to work on your health. Plus, if you're looking for a place to get health insurance, they can also help you with that.

Drug addiction poses a serious challenge since it impacts one's physical and mental health. However, the good news is that individuals who complete a drug rehabilitation program can overcome this problem. If you are interested in providing rehab services, there are a couple of things you should know. Read on to learn how to operate a rehabilitation clinic flawlessly. KNOW THE NEEDS OF YOUR CLIENTS The main purpose of drug rehab is to help different people overcome addictions. It is designed to heal the body and mind from the negative effects of addiction. It also teaches the affected individuals to learn to live without using substances. Therefore, your first step is to conduct a comprehensive assessment of each client to formulate a personalized treatment plan. Everyone has unique needs in their recovery journey. Your rehab program can start with detox which is designed to rid the body of substances, although it does not treat addiction. The person affected undergoes different therapies during treatment. Therapy helps them deal with the issues that cause substance abuse and teach them healthier ways of life. Various therapies will be applied throughout the entire treatment process. Therefore, you must choose a suitable therapy for each individual. For instance, motivational interviewing and cognitive behavioral therapy are the most common.

The National Institute for Health and Care Excellence (NICE) has recommended faricimab as treatment option for adults with wet age-related macular degeneration or diabetic macular oedema. Thousands of people in England could benefit from the recommendation of a new drug that helps to treat two leading causes of sight loss and visual impairment. Faricimab is administered as an eye injection and is being recommended as an option for treating some adults with wet age-related macular degeneration (AMD) or with diabetic macular oedema (DMO). In the key clinical trials, aflibercept, another eye injection drug used to treat AMD and DMO, was administered every 8 weeks, while faricimab dosing, based on assessments of the disease activity, allowed for an interval of up to 16 weeks between doses, and was found to be equally effective. Up to 300,000 people in England with wet age-related macular degeneration (AMD) could be eligible to receive faricimab as part of their treatment alongside just over 28,000 people with diabetic macular oedema.

The National Institute for Health and Care Excellence (NICE) has recommended pembrolizumab in combination with chemotherapy (paclitaxel or nab-paclitaxel) which is said to benefit people with triple negative breast cancer. Clinical trial evidence shows that, compared with paclitaxel, pembrolizumab combination increases how long people have before their cancer gets worse and how long they live. NICE already recommends atezolizumab in combination with chemotherapy for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer. Atezolizumab combination is recommended by NICE for people with IC equal to or greater than 1%. "This means that some people who can't have atezolizumab combination could be eligible for pembrolizumab combination," said NICE. NICE's independent appraisal committee also agreed that the pembrolizumab combination meets the higher cost-effectiveness threshold for life-extending treatments for people with a short life expectancy. Given by injection every 3 weeks, pembrolizumab (also called Keytruda and made by Merck Sharp and Dohme) is a type of immunotherapy that specifically targets triple negative breast cancer. It works by blocking the activity of a protein known as PD-L1 which is produced in larger amounts on cancerous cells than normal cells. By blocking PD-L1 it helps the person's own immune cells to attack the cancer.

The NHS on Thursday (May 5) said it has rolled out the arthritis drug baricitinib for seriously ill Covid patients. The Recovery trial, conducted by the NHS and University of Oxford, found that 13 per cent fewer severely ill patients died of Covid when treated with the drug compared to existing treatment options. Typically used to treat arthritis to reduce pain and inflammation, baricitinib can now be given to hospitalised Covid patients in addition to current treatments, and clinical studies show that this can provide benefits on top of existing treatment. The NHS has led the rollout of Covid medicines, from the discovery of dexamethasone as the world's first effective treatment, to the first vaccination outside of a clinical trial in December 2020. The NHS said baricitinib works by reducing inflammation caused by Covid-19 by blocking signals to the immune system that are causing it to attack the body.

In response to the concerning surge in youth vaping, the UK government in January announced its decision to ban disposable vapes as a measure to safeguard the health of children. Prime Minister Rishi Sunak stated that while the long-term impacts of vaping were uncertain, the nicotine present in these products can be highly addictive. Therefore, he emphasised that "marketing vapes to children is not acceptable." Now, there's a stronger reason to crack down on vape sales as a new study has revealed that vaping or the use of e-cigarettes may increase the risk of developing heart failure. The study, which involved 175,000 adults in the United States, found that those who use e-cigarettes were 19 per cent more likely to develop heart failure over a four-year period. Dr Yakubu Bene-Alhasan, lead author of the study, from MedStar Health in Baltimore, underscored that an increasing number of studies are linking e-cigarettes with harmful effects, suggesting vaping "might not be as safe as previously thought." With further research, Dr Bene-Alhasan's team plans to uncover "a lot more about the potential health consequences and improve the information out to the public."

With 118 new cases confirmed by the UK Health Security Agency (UKHSA), the total number of measles cases reported in England since 1 October 2023 has gone up to 465. According to the latest data published by the agency, West Midlands continues to see a disproportionately high rate of infections, with a sharp rise in case numbers over the last six weeks, mainly driven by cases in Birmingham. In England, there were 17 laboratory-confirmed measles cases in October, 42 in November, 161 in December, 240 in January 2024. Five more cases were confirmed last week, according to the measles statistics updated by UKHSA on 8 February. More than 70 per cent (329 of 465) of total confirmed cases were reported from the West Midlands, 13 per cent (62 of 465) from London, seven per cent (32 of 465) in Yorkshire and The Humber, and the remaining cases from other regions of England.

Reena Mehta, consultant pharmacist in the Critical Care team at NHS King's College Hospital, has been announced as chair of the Learning Division for the Intensive Care Society. Mehta took up the post with effect from 8th April, and is the first pharmacist to hold the role of Chair of the Learning Division within the Society. "It is a privilege to be part of the Society and support its life-saving work to enhance our understanding of critical illness and deliver better care to patients," "The intensive care community is made up of multiple professions, each playing a vital role within the critical care team, and I am extremely proud to be the first pharmacist appointed to this important role." In her role as chair of the Learning Division, Mehta will oversee the content of the Society's study days and be responsible for exploring new opportunities for the Intensive Care Society to provide training for our multi professional intensive care community.

Expressing apprehension over the concerning decline in the nursing workforce, Sir Julian Hartley, CEO of NHS Providers, urged the forthcoming government to bolster investment in nursing education and enhance support for student nurses. Recent analysis from the Royal College of Nursing (RCN) has projected that the NHS Long Term Workforce Plan will fall short by 10,000 new nurses by 2025. Commenting on the RCN analysis, Sir Hartley underscored the critical importance of having an adequate number of nurses to ensure the delivery of safe, high-quality patient care. "Without enough nurses, the delivery of safe, high-quality patient care is compromised," he said. He cautioned that the predicted shortfall in nurses would exacerbate existing pressures on the NHS, resulting in long waiting times, delayed treatments and staff burnout.

The Royal College of Nursing (RCN) has expressed "extreme disappointment" that the UK government offered new pay to NHS consultants, while nursing pay deal remain disputed. RCN General Secretary and Chief Executive Pat Cullen has written to new Health Secretary Victoria Atkins demanding fresh negotiations regarding this year's pay deal, and requested an urgent meeting to discuss their dispute. Pat warned that more than 100,000 RCN members in England voted for continued strike action in June, as they feel undervalued. "The government has now shown it has the political will to negotiate on pay reform for some of the highest earners in the NHS in contrast to our members who received the lowest pay rise in the public sector," she wrote in the letter. NHS nursing staff in England was awarded a five per cent pay rise 2023/24, but the union argued that it is not enough to keep up with inflation.

The Department of Health and Social Care (DHSC) has published the full text of the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG). The 2024 VPAG agreement text sets out the detailed terms of the agreement reached between DHSC, NHS England and the Association of the British Pharmaceutical Industry (ABPI) to support patient access to medicines, the financial sustainability of the NHS and the UK life sciences sector. The new voluntary scheme will come into force on 1 January 2024, following expiry of the 2019 Voluntary Scheme and shall remain in force for a period of five years, until 31 December 2028. Manufacturers or suppliers of branded medicines to the NHS have been given time till 15 January 2024 to decide whether to join the new 2024 Voluntary Scheme, or default to the updated Statutory Scheme.

The UK Health Security Agency (UKHSA) has warned that there has been a continued increase in cases of whooping cough (pertussis) across England since the start of this year. According to new data published by the agency on Thursday (7 March), 553 new cases of whooping cough were confirmed in January alone, compared with 858 cases for the whole of last year (2023). The country is witnessing a surge in whooping cough cases after a prolonged period of low case numbers, attributed to restrictions and reduced social interaction during the COVID-19 pandemic. England recorded the highest number of whooping cough cases in 2016, recording 5,949 cases. As the ongoing rise coincides with a steady decline in the vaccination rates among pregnant women and children, UKHSA has strongly encouraged mums-to-be to get the maternal pertussis vaccine so that their young baby is protected against this serious disease.

Hundreds of children in England are set to benefit from a treatment for cystic fibrosis - Kaftrio, after the UK's Medicines and Healthcare products Regulatory Agency (MHRA) confirmed an extension to its licence. With the licence extension, more than 1,300 children in England with cystic fibrosis, aged six to 11, are newly eligible for this treatment, which improves lung function and improves overall quality of life of patients. Earlier, Kaftrio was only licensed for those aged 12 and above. British patients were the first in Europe to benefit from Kaftrio, when NHS England secured a landmark deal in June 2020. NHS chief executive Amanda Pritchard said: "Since NHS staff delivered one of the fastest rollouts of Kaftrio in the world just over a year ago, the lives of thousands of patients with cystic fibrosis have been transformed. "Innovative treatments like Kaftrio are life-changing for patients and their families, and that is why the NHS has done all it can since we secured the deal for Kaftrio to ensure patients benefit as soon as possible.

The Joint Committee on Vaccination and Immunisation (JCVI) has advised booster vaccination to be offered this autumn (2023) for those at higher risk of severe Covid-19 in its interim advice to government on the coronavirus (COVID-19) vaccination programme for 2023. The JCVI also advised that for a smaller group of people, such as those who are older and those who are immunosuppressed, an extra booster vaccine dose in the spring should also be planned for. Professor Wei Shen Lim, Chair of Covid-19 vaccination on the JCVI, said: "The Covid-19 vaccination programme continues to reduce severe disease across the population, while helping to protect the NHS. That is why we have advised planning for further booster vaccines for persons at higher risk of serious illness through an autumn booster programme later this year. We will very shortly also provide final advice on a spring booster programme for those at greatest risk."